The American healthcare system is at a critical point. Specifically, a wave of lower-cost biosimilars for the world's best-selling drug Humira will launch this summer and may determine the future affordability of prescription drug prices in the U.S. If successful, these biosimilars could increase patient access to life-saving treatments and save patients and the healthcare system more than $5 billion dollars per year.
Continue Reading
